Tokyo Tape
Sign in
← CellSeed

Quarterly report · Q3

7776.TEDINET S100S7NI
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥119m2023-01-01 → 2023-09-30StandaloneNet sales
Revenue¥126m2022-01-01 → 2022-12-31StandaloneNet sales (5-year summary)
Revenue¥88m2022-01-01 → 2022-09-30StandaloneNet sales
Operating income−¥577m2023-01-01 → 2023-09-30StandaloneOperating income
Operating income−¥564m2022-01-01 → 2022-09-30StandaloneOperating income
Ordinary income−¥587m2023-01-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥754m2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥571m2022-01-01 → 2022-09-30StandaloneOrdinary income
Profit before tax−¥584m2023-01-01 → 2023-09-30StandaloneIncome before income taxes
Profit before tax−¥572m2022-01-01 → 2022-09-30StandaloneIncome before income taxes
Net income−¥585m2023-01-01 → 2023-09-30StandaloneProfit loss
Net income−¥760m2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Net income−¥574m2022-01-01 → 2022-09-30StandaloneProfit loss
Total assets¥2.6bnat 2023-09-30StandaloneAssets
Total assets¥1.5bnat 2022-12-31StandaloneAssets
Total assets¥1.5bnat 2022-09-30StandaloneTotal assets (5-year summary)
Total liabilities¥390mat 2023-09-30StandaloneLiabilities
Total liabilities¥366mat 2022-12-31StandaloneLiabilities
Net assets / equity¥2.3bnat 2023-09-30StandaloneNet assets
Net assets / equity¥1.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2022-09-30StandaloneNet assets (5-year summary)
Cash and deposits¥2.2bnat 2023-09-30StandaloneCash and deposits
Cash and deposits¥1.1bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥-20.952023-01-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-7.622023-07-01 → 2023-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.312022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.382022-01-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-9.82022-07-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio84.4%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio74.8%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio71.3%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Shares issued30,889,419at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued24,422,619at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued22,159,419at 2022-09-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-09-30−¥147m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue2023-01-01 → 2023-09-30¥8m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue external2023-01-01 → 2023-09-30¥8m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentsegment profit2023-01-01 → 2023-09-30−¥394m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue2023-01-01 → 2023-09-30¥111m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue external2023-01-01 → 2023-09-30¥111m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentsegment profit2023-01-01 → 2023-09-30−¥36m
—segment totalrevenue2023-01-01 → 2023-09-30¥119m
—segment totalrevenue external2023-01-01 → 2023-09-30¥119m
—segment totalsegment profit2023-01-01 → 2023-09-30−¥430m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥147m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue2022-01-01 → 2022-09-30¥7m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue external2022-01-01 → 2022-09-30¥7m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentsegment profit2022-01-01 → 2022-09-30−¥347m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue2022-01-01 → 2022-09-30¥81m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue external2022-01-01 → 2022-09-30¥81m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentsegment profit2022-01-01 → 2022-09-30−¥70m
—segment totalrevenue2022-01-01 → 2022-09-30¥88m
—segment totalrevenue external2022-01-01 → 2022-09-30¥88m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥418m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 307
ItemContextValueUnit
Interest expenses noeCurrentYTDDuration_NonConsolidatedMember575000JPY
Stock issuance cost prior noePrior1YTDDuration_NonConsolidatedMember7887000JPY
Stock issuance cost prior noeCurrentYTDDuration_NonConsolidatedMember11260000JPY
Non operating expensesPrior1YTDDuration_NonConsolidatedMember8515000JPY
Non operating expensesCurrentYTDDuration_NonConsolidatedMember11836000JPY
Ordinary incomePrior1YTDDuration_NonConsolidatedMember-570781000JPY
Ordinary incomeCurrentYTDDuration_NonConsolidatedMember-586995000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration_NonConsolidatedMember2358000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration_NonConsolidatedMember609000JPY
Gain on sales of subsidiaries and affiliates stocks eiPrior1YTDDuration_NonConsolidatedMember－JPY
Gain on sales of subsidiaries and affiliates stocks eiCurrentYTDDuration_NonConsolidatedMember15759000JPY
Extraordinary incomePrior1YTDDuration_NonConsolidatedMember2358000JPY
Extraordinary incomeCurrentYTDDuration_NonConsolidatedMember16369000JPY
Impairment loss elPrior1YTDDuration_NonConsolidatedMember3104000JPY
Impairment loss elCurrentYTDDuration_NonConsolidatedMember13172000JPY
Extraordinary lossPrior1YTDDuration_NonConsolidatedMember3104000JPY
Extraordinary lossCurrentYTDDuration_NonConsolidatedMember13172000JPY
Income before income taxesPrior1YTDDuration_NonConsolidatedMember-571527000JPY
Income before income taxesCurrentYTDDuration_NonConsolidatedMember-583798000JPY
Income taxes currentPrior1YTDDuration_NonConsolidatedMember2850000JPY
Income taxes currentCurrentYTDDuration_NonConsolidatedMember712000JPY
Income taxesPrior1YTDDuration_NonConsolidatedMember2850000JPY
Income taxesCurrentYTDDuration_NonConsolidatedMember712000JPY
Profit lossPrior1YTDDuration_NonConsolidatedMember-574377000JPY
Profit lossCurrentYTDDuration_NonConsolidatedMember-584510000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember81230000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember6955000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember88185000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember88185000JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember－JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember81230000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember6955000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember88185000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration_NonConsolidatedMember88185000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember-70433000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember-347476000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember-417909000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember-146560000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-564470000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember111403000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember7799000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember119202000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember119202000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-09-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass